Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 4/2019

01.04.2019 | Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)

Cognitive Frailty in Older People with Type 2 Diabetes Mellitus: the Central Role of Hypoglycaemia and the Need for Prevention

verfasst von: A. H. Abdelhafiz, A. J. Sinclair

Erschienen in: Current Diabetes Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To highlight the central role of hypoglycaemia in the causation of cognitive frailty and explore ways of recognition and prevention of hypoglycaemia.

Recent Findings

Cognitive frailty is an emerging new concept defined as the concomitant presence of physical frailty and cognitive impairment. In older people with diabetes, cognitive frailty is associated with an increased risk of mortality greater than from either physical frailty or cognitive impairment alone. Hypoglycaemia is directly associated with increased risk of cognitive impairment and physical frailty which are the two components of cognitive frailty. The incidence of hypoglycaemia in older people with diabetes is rising and hypoglycaemia-related hospitalisation has overtaken that of hyperglycaemia.

Summary

Recognition of hypoglycaemic episodes in old age remains challenging which leads to misdiagnoses and under-reporting. Therefore, hypoglycaemia prevention strategies are needed. Research is still required to investigate whether prevention of hypoglycaemia would lead to a reduction in the incidence of cognitive frailty.
Literatur
1.
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.CrossRef
2.
Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66:1210–5.CrossRef
3.
Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;10:819–29.CrossRef
4.
Thein FS, Li Y, Nyunt MSZ, Gao Q, Wee SL, Ng TP. Physical frailty and cognitive impairment is associated with diabetes and adversely impact functional status and mortality. Postgrad Med. 2018;130:561–7.CrossRef
5.
Panza F, D'Introno A, Colacicco AM, et al. Cognitive frailty: predementia syndrome and vascular risk factors. Neurobiol Aging. 2006;27:933–40.CrossRef
6.
•• Kelaiditi E, Cesari M, Canevelli M, et al. Cognitive frailty: rational and definition from an (IANA/IAGG) international consensus group. J Nutr Health Aging. 2013;9:726–34. This is a consensus report introducing the new concept of cognitive frailty. CrossRef
7.
Thorpe CT, Thorpe JM, Kind AJ, et al. Receipt of monitoring of diabetes mellitus in older adults with comorbid dementia. J Am Geriatr Soc. 2012;60:644–51.CrossRef
8.
Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cognitive decline and dementia in elderly patients with diabetes. Diabetes Metab. 2014;40:331–7.CrossRef
9.
Gadsby R, Barker P, Sinclair A. People living with diabetes resident in nursing homes–assessing levels of disability and nursing needs. Diabet Med. 2011;28:778–80.CrossRef
10.
Passaro A, Nora ED, Morieri ML, et al. Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population. J Gerontol A Biol Sci Med Sci. 2015;70:294–302.CrossRef
11.
Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, et al. Is insulin resistant brain state a central feature of the metabolic cognitive syndrome? J Alzheimers Dis. 2010;21:57–63.CrossRef
12.
Li J, Wang YJ, Zhang M, the Chongqing Ageing Study Group, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76:1485–91.CrossRef
13.
Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42:484–91.CrossRef
14.
Wong E, Backholer K, Gearon E, Harding J, Freak-Poli R, Stevenson C, et al. Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1:106–14.CrossRef
15.
Chiu CJ, Wray LA. Physical disability trajectories in older Americans with and without diabetes: the role of age, gender, race or ethnicity, and education. Gerontologist. 2011;51:51–63.CrossRef
16.
Maggi S, Noale M, Gallina P, Marzari C, Bianchi D, Limongi F, et al. Physical disability among older Italians with diabetes. The ILSA study. Diabetologia. 2004;47:1957–62.CrossRef
17.
Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, et al. Health, aging, and body composition study. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30:1507–12.CrossRef
18.
Lee S, Lee S, Harada K, Bae S, Makizako H, Doi T, et al. Relationship between chronic kidney disease with diabetes or hypertension and frailty in community-dwelling Japanese older adults. Geriatr Gerontol Int. 2017;17:1527–33.PubMed
19.
Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ. Frailty, sarcopenia and diabetes. J Am Med Dir Assoc. 2014;15:853–9.CrossRef
20.
Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm-issues and controversies. J Gerontol A Biol Sci Med Sci. 2009;62A:731–7.
21.
Gruenewald TL, Seeman TE, Karlamangla AS, Sarkisian CA. Allostatic load and frailty in older adults. J Am Geriatr Soc. 2009;57:1525–31.CrossRef
22.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56A:M146–M56.CrossRef
23.
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.CrossRef
24.
Pialoux T, Goyard J, Lesourd B. Screening tools for frailty in primary health care: a systematic review. Geriatr Gerontol Int. 2012;12:189–97.CrossRef
25.
Heuberger RA. The frailty syndrome: a comprehensive review. J Nutr Gerontol Geriatr. 2011;30:315–68.CrossRef
26.
27.
De Vries NM, Staal JB, van Ravensberg CD, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2011;10:104–14.CrossRef
28.
Jafari B, Britton ME. Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention. J Pharm Pract Res. 2015;45:459–69.CrossRef
29.
30.
31.
Chen LK, Lin MH, Lai HY, Hwang SJ. Care of patients with diabetes mellitus in long-term care facilities in Taiwan: diagnosis, glycemic control, hypoglycemia, and functional status. J Am Geriatr Soc. 2008;56:1975–6.CrossRef
32.
Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab. 2009;297:E194–201.CrossRef
33.
Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, Strotmeyer ES, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173:1300–6.CrossRef
34.
Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk ofdementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72.CrossRef
35.
Lin CH, Sheu WHH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273:102–10.CrossRef
36.
Chin SO, Rhee SY, Chon S, Baik SH, Park Y, Nam MS, et al. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract. 2016;122:54–61.CrossRef
37.
• Mehta HB, Mehta V, Goodwin JS. Association of hypoglycemia with subsequent dementia in older patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2017;72:1110–6. This is a large study confirming the relationship between hypoglycaemia and incident dementia in a dose guarded effect. PubMed
38.
Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014;37:507–15.CrossRef
39.
Haroon NN, Austin PC, Shah BR, Wu J, Gill SS, Booth GL. Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care. 2015;38:1868–75.CrossRef
40.
Duning T, van den Heuvel I, Dickmann A, Volkert T, Wempe C, Reinholz J, et al. Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction. Diabetes Care. 2010;33:639–44.CrossRef
41.
Aung PP, Strachan MW, Frier BM, Butcher I, Deary IJ, Price JF. Severe hypoglycaemia and late-life cognitive ability in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabet Med. 2012;29:328–36.CrossRef
42.
Gao Y, Xiao Y, Miao R, Zhao J, Zhang W, Huang G, et al. The characteristic of cognitive function in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015;109:299–305.CrossRef
43.
Lee AK, Rawlings AM, Lee CJ, Gross AL, Huang ES, Sharrett AR, et al. Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) cohort study. Diabetologia. 2018;61:1956–65.CrossRef
44.
45.
Wang F, Zhao M, Han Z, Li D, Zhang S, Zhang Y, et al. Long-term subclinical hyperglycemia and hypoglycemia as independent risk factors for mild cognitive impairment in elderly people. Tohoku J Exp Med. 2017;242:121–8.CrossRef
46.
Bruce DG, Davis WA, Casey GP, Starkstein SE, Clarnette RM, Foster JK, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia. 2008;51:241–8.CrossRef
47.
Bruce DG, Davis WA, Casey GP, Clarnette RM, Brown SGA, Jacobs IG, et al. Severe hypoglycemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia. 2009;52:1808–15.CrossRef
48.
Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al. ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10:969–77.CrossRef
49.
de Galan BE, Zoungas S, Chalmers J, ADVANCE Collaborative Group, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52:2328–36.CrossRef
50.
51.
• Zaslavsky O, Walker RL, Crane PK, Gray SL, Larson EB. Glucose levels and risk of frailty. J Gerontol A Biol Sci Med Sci. 2016;71:1223–9. This is a large prospective study that investigated the relationship between blood glucose levels and incident frailty in persons with or without diabetes. CrossRef
52.
Yanagita I, Fujihara Y, Eda T, Tajima M, Yonemura K, Kawajiri T, et al. Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients. J Diabetes Investig. 2018;9:419–25.CrossRef
53.
Morita T, Okuno T, Himeno T, Watanabe K, Nakajima K, Koizumi Y, et al. Glycemic control and disability-free survival in hypoglycemic agent-treated community-dwelling older patients with type 2 diabetes mellitus. Geriatr Gerontol Int. 2017;17:1858–65.CrossRef
54.
de Decker L, Hanon O, Boureau AS, Chapelet G, Dibon C, Pichelin M, et al. Association between hypoglycemia and the burden of comorbidities in hospitalized vulnerable older diabetic patients: a cross-sectional, population-based study. Diabetes Ther. 2017;8:1405–13.CrossRef
55.
Abbatecola AM, Bo M, Armellini F, D'Amico F, Desideri G, Falaschi P, et al. Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: results from the DIMORA study. Metabolism. 2015;64:1500–6.CrossRef
56.
Mattishent K, Loke YK. Meta-analysis: association between hypoglycaemia and serious adverse events in older patients. J Diabetes Complicat. 2016;30:811–8.CrossRef
57.
Hung YC, Lin CC, Chen HJ, Chang MP, Huang KC, Chen YH, et al. Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study. Osteoporos Int. 2017;28:2053–60.CrossRef
58.
Robertsona DA, Savva GM, Kenny RA. Frailty and cognitive impairment—a review of the evidence and causal mechanisms. Ageing Res Rev. 2013;12:840–51.CrossRef
59.
Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18:135–41.CrossRef
60.
Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K. Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci. 2010;65A:377–81.CrossRef
61.
62.
Abdelhafiz AH, Koay L, Sincalir AJ. The emergence of frailty may lead to a state of burnt out type 2 diabetes. J Frailty Aging. 2016;5:162–7.PubMed
63.
64.
Nicolucci A, Pintaudi B, Rossi MC, Messina R, Dotta F, Frontoni S, et al. The social burden of hypoglycemia in the elderly. Acta Diabetol. 2015;52:677–85.CrossRef
65.
Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.CrossRef
66.
Bonds DE, Miller ME, Dudl J, Feinglos M, Ismail-Beigi F, Malozowski S, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord. 2012;12. https://​doi.​org/​10.​1186/​1472-6823-12-5.
67.
Hope SV, Taylor PJ, Shields BM, Hattersley AT, Hamilton W. Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Prim Care Diabetes. 2018;12:139–46.CrossRef
68.
Lipska KJ, Krumholz H, Soones T, et al. Polypharmacy in the aging patient. A review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315:1034–45.CrossRef
69.
70.
Sinclair A, Morley JE, Rodriguez-Mañas L, Paolisso G, Bayer T, Zeyfang A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. 2012;13:497–502.
71.
Sinclair AJ, Abdelhafiz A, Dunning T, Izquierdo M, Rodriguez Manas L, Bourdel-Marchasson I, et al. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J Frailty Aging. 2018;7:10–20.PubMed
72.
Sinclair AJ, Paolisso G, Castro M, Bourdel-Marchasson I, Gadsby R, Rodriguez Mañas L. European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37(Suppl 3):S27–38.CrossRef
73.
American Diabetes Association. 11. Older adults: standards of medical care in diabetes—2018. Diabetes Care. 2018;41:S119–25.CrossRef
74.
Munshi MN, Segal AR, Suhl E, Staum E, Desrochers L, Sternthal A, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362–4.CrossRef
75.
Ravona-Springer R, Heymann A, Schmeidler J, Moshier E, Godbold J, Sano M, et al. Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes. PLoS One. 2014;9:e97384.CrossRef
76.
Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:476–86.CrossRef
77.
Cui X, Amir A, Manor BD, et al. Multi-scale glycemic variability: a link to gray matter atrophy and cognitive decline in type 2 diabetes. Plos One. 2014;9:e 86284.CrossRef
78.
García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P. Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer’s disease? Rev Neurol. 2014;59:517–24.PubMed
79.
Galimberti D, Scarpini E. Pioglitazone for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2017;26:97–101.CrossRef
80.
Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175:356–62.CrossRef
81.
Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38:588–95.PubMedPubMedCentral
82.
Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176:1023–5.CrossRef
83.
Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, et al. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. 2018;379:547–56.CrossRef
84.
Bunn F, Burn AM, Robinson L, Poole M, Rait G, Brayne C, et al. Healthcare organisation and delivery for people with dementia and comorbidity: a qualitative study exploring the views of patients, carers and professionals. BMJ Open. 2017;7:e013067.CrossRef
85.
Sinclair A. Diabetes care for older people: a practical view on management. Diabetes and Primary Care. 2011;13:29–38.
86.
Gulli G, Frasson S, Borzı’ V, et al. Effectiveness of an educational intervention on the management of type 2 diabetic patients hospitalized in Internal Medicine: results from the FADOI-DIAMOND study. Acta Diabetol. 2014;51:765–70.CrossRef
87.
Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, Kirsh S, Kullgren JT, Prenovost K, et al. Appropriate prescribing for patients with diabetes at high risk for hypoglycemia: national survey of veterans affairs health care professionals. JAMA Intern Med. 2015;175:1994–6.CrossRef
88.
Karter AJ, Warton EM, Lipska KJ, et al. Development and validation of a tool to identify patients with type 2 diabetes at high risk of hypoglycemia-related emergency department or hospital use. JAMA Intern Med. 2017;36:3535–42.
89.
Vimalananda VG, DeSotto K, Chen T, Mullakary J, Schlosser J, Archambeault C, et al. A quality improvement program to reduce potential overtreatment of diabetes among veterans at high risk of hypoglycemia. Diabetes Spectr. 2017;30:211–6.CrossRef
Metadaten
Titel
Cognitive Frailty in Older People with Type 2 Diabetes Mellitus: the Central Role of Hypoglycaemia and the Need for Prevention
verfasst von
A. H. Abdelhafiz
A. J. Sinclair
Publikationsdatum
01.04.2019
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 4/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1135-4

Weitere Artikel der Ausgabe 4/2019

Current Diabetes Reports 4/2019 Zur Ausgabe

Genetics (AP Morris, Section Editor)

The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges

Microvascular Complications—Nephropathy (M Afkarian and B Roshanravan, Section Editors)

The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps

Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)

Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes

Microvascular Complications—Retinopathy (DL Chao and G Yiu, Section Editors)

Retinal Neurodegeneration as an Early Manifestation of Diabetic Eye Disease and Potential Neuroprotective Therapies

Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)

Perioperative Management of Diabetes Mellitus: Novel Approaches

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise